首页> 外文OA文献 >Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197

【2h】

Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197

机译：并发多柔比星加多西他赛在并发0至3个阳性腋窝淋巴结的可手术乳腺癌中比并发多柔比星加多环磷酰胺疗效不佳：北美乳腺癌群间试验E 2197

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Goldstein, Lori J.; O'Neill, Anne; Sparano, Joseph A.; Perez, Edith A.; Shulman, Lawrence N.; Martino, Silvana; Davidson, Nancy E.;
展开▼
作者单位

展开▼
年度 2008
总页数
原文格式 PDF
正文语种 en
中图分类

相似文献

外文文献
中文文献
专利

1. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. [J] . Goldstein LJ, ONeill A, Sparano JA, Journal of Clinical Oncology . 2008,第25期

机译：并发阿霉素加多西他赛在并发腋下淋巴结阳性0至3例的可手术乳腺癌中比并发阿霉素加环磷酰胺不更有效：北美乳腺癌小组间试验E 2197。
2. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. [J] . Goldstein LJ, ONeill A, Sparano JA, Journal of Clinical Oncology . 2008,第25期

机译：并发阿霉素加多西他赛在并发腋下淋巴结阳性0至3例的可手术乳腺癌中比并发阿霉素加环磷酰胺不更有效：北美乳腺癌小组间试验E 2197。
3. Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer-8-year results of the breast international group 02-98 phase III trial [J] . OakmanC., FrancisP.A., CrownJ., Annals of oncology: official journal of the European Society for Medical Oncology . 2013,第5期

机译：国际乳腺癌组织02-98期III期试验的8年结果显示，序贯阿霉素-多西他赛与同时使用阿霉素和多西他赛相比在淋巴结阳性乳腺癌中具有总体生存优势
4. North American Adjuvant Breast Cancer Trials [C] . International Conference on "Adjuvant Therapy of Primary Breast Cancer" . 1998

机译：北美佐剂乳腺癌试验
5. Investigating the Anti-Cancer Effects of Doxorubicin and Quercetin Combination on Breast Cancer [D] . Ho, Wai Hung Michael. 2018

机译：调查多柔比星和槲皮素组合对乳腺癌的抗癌作用
6. Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197 [O] . Lori J. Goldstein, Anne ONeill, Joseph A. Sparano, -1

机译：并发多柔比星加多西他赛在并发0至3个阳性腋窝淋巴结的可手术乳腺癌中比并发多柔比星加多环磷酰胺疗效不佳：北美乳腺癌群间试验E 2197
7. NEOADJUVANT WEEKLY NAB-PACLITAXEL PLUS CARBOPLATIN FOLLOWED BY DOXORUBICIN PLUS CYCLOPHOSPHAMIDE WITH BEVACIZUMAB ADDED CONCURRENTLY TO CHEMOTHERAPY FOR OPERABLE TRIPLE-NEGATIVE INVASIVE BREAST CANCER [O] . Jasgit C. Sachdev, Jessica N. Snider, Jeffrey W. Allen, 1969

机译：Neoadjuvant每周Nab-Paclitaxel加上卡铂，然后是Doxorubicin加上环磷酰胺与贝伐单抗同时添加到可操作的三阴性侵入性乳腺癌中

Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197

著录项

相似文献

相关主题

期刊订阅